⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Impact of Baseline Polyneuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study (P2-11.015)

Dianna Quan Marco Luigetti John L. Berk Isabel Conceição Yohei Misumi Chi‐Chao Chao Shaun Bender Emre Aldinc Joshua R. Vest David Adams

View at Publisher

Ask AI

Bookmark

Share

Abstract

This analysis evaluates the impact of baseline polyneuropathy severity on response to vutrisiran treatment in patients with hereditary transthyretin-mediated (ATTRv; v for variant) amyloidosis with polyneuropathy during the Phase 3 HELIOS-A study (NCT03759379).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Quan et al. (2024) studied this question.

synapsesocial.com/papers/68e6feb4b6db643587678b4b https://doi.org/10.1212/wnl.0000000000206112

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extensionRCT · 2026
2Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-AOriginal Research · 2026 · 1 citations
3HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathycohort · 2025 · 3 citations
4Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With CardiomyopathyRCT · 2025 · 18 citations
5Efficacy of Eplontersen According to Baseline Polyneuropathy Severity in Patients with Hereditary Transthyretin Amyloidosis: A Subgroup Analysis of the NEURO-TTRansform Index Study (S32.009)Meta-Analysis · 2026

More related papers

Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial2026
Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial2025
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B2025

More from Neurology

Antidopaminergic Medications and Clinical Outcomes in Huntington DiseaseThu,
Recanalization After Acute Cervical Artery DissectionTue,